AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective-Reference-Cited by-同舟云学术

AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective

Published:2015-11-20 Issue:8 Volume:59 Page:3593-3608
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Myers Samuel H.¹,Brunton Valerie G.¹,Unciti-Broceta Asier¹

Affiliation:

1. Edinburgh Cancer Research UK Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.

Funder

Cancer Research UK

Scottish Power Ltd.

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.5b01273

Reference115 articles.

1. The protein tyrosine kinase family of the human genome

2. Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers

3. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase.

4. Axl and Growth Arrest Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme

5. TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase

Cited by 162 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of Dual MER/AXL Kinase Inhibitors as Bifunctional Small Molecules for Inhibiting Tumor Growth and Enhancing Tumor Immune Microenvironment;Journal of Medicinal Chemistry;2024-06-24

2. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update;Pharmacological Research;2024-02

3. Structure-activity relationship study of 1,6-naphthyridinone derivatives as selective type II AXL inhibitors with potent antitumor efficacy;European Journal of Medicinal Chemistry;2024-02

4. Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment;International Journal of Molecular Sciences;2024-01-23

5. Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases;Pharmacological Research;2024-01